Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Not only can different lung diseases look much the same in chest imaging, but distinct diagnoses may present widely dissimilar image patterns in the same patient at the same timepoint, too.

Physicians do not currently have a sound method of zeroing in on this concern, but Washington University researchers may have found an answer.